Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled study of AG-348 (mitapivat) in adults with pyruvate kinase deficiency not regularly transfused
jRCT2031220315Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- May 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mitapivat in pyruvate kinase deficiency (PKD) (4 arms), sponsored by Agios Pharmaceuticals. Primary endpoint: Hemoglobin response rate. Started May 2019; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on jRCT2031220315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220315.